AR056815A1 - PROCESO PARA PREPARAR MONTELUKAST, INTERMEDIARIOS DEL MISMO Y SUS SALES DE ADICIoN Y PROCEDIMIENTO DE PURIFICACIoN DE ÉSTOS Y DE MONTELUKAST - Google Patents
PROCESO PARA PREPARAR MONTELUKAST, INTERMEDIARIOS DEL MISMO Y SUS SALES DE ADICIoN Y PROCEDIMIENTO DE PURIFICACIoN DE ÉSTOS Y DE MONTELUKASTInfo
- Publication number
- AR056815A1 AR056815A1 ARP060105061A ARP060105061A AR056815A1 AR 056815 A1 AR056815 A1 AR 056815A1 AR P060105061 A ARP060105061 A AR P060105061A AR P060105061 A ARP060105061 A AR P060105061A AR 056815 A1 AR056815 A1 AR 056815A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compound
- methyl magnesium
- montelukast
- acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/75—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Abstract
REIVINDICACIoN 1.- Un proceso para preparar un compuesto de la formula (1) o (1a) en donde R es un grupo alquilo C1 a C4 que comprende la etapa de hacer reaccionar un compuesto de formula (2) o un ácido o una sal de adicion del mismo con un haluro de metil magnesio seleccionado de clorro de metil magnesio, bromuro de metil magnesio, ioduro de metil magnesio y combinaciones de los mismos, para formar un compuesto de formula (3) o una sal de adicion de ácido del mismo. REIVINDICACIoN 25.- Un proceso para preparar el compuesto de formula (2) y/o una sal de adicion de ácido del mismo, que comprende hacer reaccionar el compuesto de formula (4) con un haluro de metil magnesio seleccionado de cloruro de metil magnesio, bromuro de metil magnesio o ioduro de metil magnesio para formar un compuesto de formula (2) y opcionalmente convertir el compuesto (2) en la sal de adicion de ácido, preferiblemente en el clorhidrato (2a), en donde preferiblemente dicha reaccion es llevada a cabo en una mezcla de un solvente hidrocarbonado y un co-solvente etéreo. REIVINDICACIoN 30.- Un proceso para la purificacion del compuesto (2) que comprende una cristalizacion del compuesto (2) a partir de un solvente que comprende una mezcla de un éter cíclico líquido (por ej. tetrahidrofurano o dioxano) con un segundo líquido preferiblemente seleccionado de un alcohol C1-C4 (por ej. metanol o etanol), éster C2-C6 (por ej. acetato de etilo), hidrocarburo C4-C8 (por ej. tolueno) o cetona C3-C8 (por ej. acetona) y mezclas de los mismos. REIVINDICACIoN 35.- Un proceso para la purificacion del ácido montelukast de la formula (1) que comprende la(s) etapa(s) de i) filtrar una solucion de ácido montelukast en tolueno a través de un sorbente polar, tal como gel de sílice, y opcionalmente precipitar el ácido montelukast; y/o ii) cristalizar ácido montelukast a partir de un solvente protico tal como etanol bajo la ausencia de luz. REIVINDICACION 36.- Un compuesto de formula (2) o una sal de adicion del mismo, en donde preferiblemente el compuesto es una sal clorhidrato de formula (2a). REIVINDICACIoN 38.- El compuesto de formula (5) o (6) en donde R es un grupo alquilo C1-C4, preferiblemente un grupo metilo. REIVINDICACIoN 39.- Una sal de adicion de ácido del compuesto de la formula (7) preferiblemente una sl tosilato de la formula (7b) o una sal bensilato de la formula(7c). REIVINDICACION 40.- Una sal de adicion del ácido compuesto de la formula (4), preferiblemente la sal clorhidrato de la formula (4a) o el bensilato de la formula 4b).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73775205P | 2005-11-18 | 2005-11-18 | |
| US79442906P | 2006-04-24 | 2006-04-24 | |
| US82438206P | 2006-09-01 | 2006-09-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056815A1 true AR056815A1 (es) | 2007-10-24 |
Family
ID=37685804
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060105062A AR057908A1 (es) | 2005-11-18 | 2006-11-17 | Proceso para preparar montelukast e intermediarios del mismo |
| ARP060105063A AR057909A1 (es) | 2005-11-18 | 2006-11-17 | Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico. |
| ARP060105061A AR056815A1 (es) | 2005-11-18 | 2006-11-17 | PROCESO PARA PREPARAR MONTELUKAST, INTERMEDIARIOS DEL MISMO Y SUS SALES DE ADICIoN Y PROCEDIMIENTO DE PURIFICACIoN DE ÉSTOS Y DE MONTELUKAST |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060105062A AR057908A1 (es) | 2005-11-18 | 2006-11-17 | Proceso para preparar montelukast e intermediarios del mismo |
| ARP060105063A AR057909A1 (es) | 2005-11-18 | 2006-11-17 | Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico. |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US7476748B2 (es) |
| EP (3) | EP1960362A1 (es) |
| JP (1) | JP2009515922A (es) |
| AR (3) | AR057908A1 (es) |
| AT (1) | ATE497493T1 (es) |
| AU (3) | AU2006314728A1 (es) |
| CA (3) | CA2629840A1 (es) |
| DE (1) | DE602006019979D1 (es) |
| IL (1) | IL185129A0 (es) |
| NO (1) | NO20074188L (es) |
| PT (1) | PT1954679E (es) |
| WO (3) | WO2007057225A2 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1831171A4 (en) * | 2004-11-19 | 2010-09-15 | Matrix Lab Ltd | PROCESS FOR THE PREPARATION OF NEW MONTELUKAST SODIUM AMORPHOUS |
| ATE497492T1 (de) | 2005-07-05 | 2011-02-15 | Teva Pharma | Reinigung von montelukast |
| AR057908A1 (es) * | 2005-11-18 | 2007-12-26 | Synthon Bv | Proceso para preparar montelukast e intermediarios del mismo |
| EP2014650A1 (en) * | 2007-07-13 | 2009-01-14 | Lonza Ag | Process and intermediate for the production of an intermediate in the production of montelukast |
| ES2320077B1 (es) | 2007-07-31 | 2010-02-26 | Moehs Iberica, S.L. | Proceso de preparacion de un antagonista de leucotrienos y de un intermedio del mismo. |
| CN102046602A (zh) * | 2008-04-25 | 2011-05-04 | 斯索恩有限公司 | 制备孟鲁司特中间体的方法 |
| EP2552892A1 (en) | 2010-03-31 | 2013-02-06 | KRKA, D.D., Novo Mesto | Efficient synthesis for the preparation of montelukast and novel crystalline form of intermediates therein |
| SG185389A1 (en) | 2010-05-03 | 2012-12-28 | Teikoku Pharma Usa Inc | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
| TWI450275B (zh) * | 2010-05-19 | 2014-08-21 | Wistron Corp | 可提升寫入保護之記憶體系統及相關方法 |
| US8471030B2 (en) | 2010-12-06 | 2013-06-25 | Orochem Technologies Inc. | Purification of montelukast using simulated moving bed |
| EP2502910A1 (en) * | 2011-03-15 | 2012-09-26 | Laboratorios Lesvi, S.L. | Camphorsulfonic salt of a key Montelukast intermediate |
| JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR930011486B1 (ko) * | 1985-08-06 | 1993-12-08 | 베링거 만하임 이탈리아 에스.피.에이. | 제약상 유효한 2-티오메틸-치환-1,4-디히드로피리딘 |
| CA2038178A1 (en) | 1990-04-05 | 1991-10-06 | Carl C. Greco | Niobium alkoxyalkoxides and process for formation |
| US5266568A (en) | 1990-10-12 | 1993-11-30 | Merck Frosst Canada, Inc. | Hydroxyalkylquinoline ether acids as leukotriene antagonists |
| US5856322A (en) | 1990-10-12 | 1999-01-05 | Merck Frosst Canada, Inc. | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists |
| CA2053216C (en) * | 1990-10-12 | 2003-04-08 | Michel L. Belley | Saturated hydroxyalkylquinoline acids as leukotriene antagonists |
| ATE165088T1 (de) | 1990-10-12 | 1998-05-15 | Merck Frosst Canada Inc | Ungesättigte hydroxyalkylchinolinsäuren als leukotrien-antagonisten |
| US5565473A (en) | 1990-10-12 | 1996-10-15 | Merck Frosst Canada, Inc. | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists |
| IE920499A1 (en) * | 1991-02-21 | 1992-08-26 | Merck Frosst Canada Inc | Quinoline-containing ketoacids as leukotriene antagonists |
| US5270324A (en) | 1992-04-10 | 1993-12-14 | Merck Frosst Canada, Inc. | Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists |
| TW416948B (en) | 1993-12-28 | 2001-01-01 | Merck & Co Inc | Process for the preparation of leukotriene antagonists |
| GB9423511D0 (en) | 1994-11-22 | 1995-01-11 | Glaxo Wellcome Inc | Compositions |
| US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
| US5523477A (en) | 1995-01-23 | 1996-06-04 | Merck & Co., Inc. | Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid |
| US5869673A (en) | 1997-02-28 | 1999-02-09 | Merck & Co., Inc. | Process for 3-(2-(7-chloro-2-quinolinyl)ethenyl) - benzaldehyde |
| CN1420113A (zh) | 2001-11-16 | 2003-05-28 | 北京上地新世纪生物医药研究所 | 孟鲁司特钠的制备方法及其制备中间体 |
| CN1171873C (zh) * | 2001-12-26 | 2004-10-20 | 北京上地新世纪生物医药研究所 | 一种孟鲁司特钠的制备方法及其制备中间体 |
| US20050107612A1 (en) * | 2002-12-30 | 2005-05-19 | Dr. Reddy's Laboratories Limited | Process for preparation of montelukast and its salts |
| US20040265375A1 (en) | 2003-04-16 | 2004-12-30 | Platteeuw Johannes J. | Orally disintegrating tablets |
| EP1678139B1 (en) | 2003-10-10 | 2011-08-31 | Synhton B.V. | Solid-state montelukast |
| EP1708708A1 (en) * | 2004-01-30 | 2006-10-11 | Teva Pharmaceutical Industries Ltd. | Montelukast free acid polymorphs |
| US7189853B2 (en) * | 2004-04-15 | 2007-03-13 | Dr. Reddy's Laboratories Limited | Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts |
| US7829716B2 (en) * | 2004-04-30 | 2010-11-09 | Synthon Pharmaceuticals, Inc. | Process for making montelukast and intermediates therefor |
| US7501517B2 (en) * | 2004-04-30 | 2009-03-10 | Synthon Ip, Inc. | Process for making montelukast and intermediates therefor |
| ATE500225T1 (de) * | 2004-07-19 | 2011-03-15 | Matrix Lab Ltd | Verfahren zur herstellung von montelukast und salzen davon |
| ITMI20050247A1 (it) * | 2005-02-18 | 2006-08-19 | Chemi Spa | Processo per la preparazione di montelukast |
| AR057908A1 (es) * | 2005-11-18 | 2007-12-26 | Synthon Bv | Proceso para preparar montelukast e intermediarios del mismo |
-
2006
- 2006-11-17 AR ARP060105062A patent/AR057908A1/es not_active Application Discontinuation
- 2006-11-17 AR ARP060105063A patent/AR057909A1/es not_active Application Discontinuation
- 2006-11-17 AR ARP060105061A patent/AR056815A1/es not_active Application Discontinuation
- 2006-11-20 CA CA002629840A patent/CA2629840A1/en not_active Abandoned
- 2006-11-20 US US11/561,689 patent/US7476748B2/en not_active Expired - Fee Related
- 2006-11-20 PT PT06818694T patent/PT1954679E/pt unknown
- 2006-11-20 EP EP06818693A patent/EP1960362A1/en not_active Withdrawn
- 2006-11-20 AU AU2006314728A patent/AU2006314728A1/en not_active Abandoned
- 2006-11-20 EP EP06818694A patent/EP1954679B1/en not_active Not-in-force
- 2006-11-20 AT AT06818694T patent/ATE497493T1/de not_active IP Right Cessation
- 2006-11-20 AU AU2006314726A patent/AU2006314726A1/en not_active Abandoned
- 2006-11-20 DE DE602006019979T patent/DE602006019979D1/de active Active
- 2006-11-20 US US11/561,724 patent/US7601741B2/en not_active Expired - Fee Related
- 2006-11-20 CA CA002598093A patent/CA2598093A1/en not_active Abandoned
- 2006-11-20 US US11/561,732 patent/US7786138B2/en not_active Expired - Fee Related
- 2006-11-20 JP JP2008540534A patent/JP2009515922A/ja not_active Withdrawn
- 2006-11-20 WO PCT/EP2006/011127 patent/WO2007057225A2/en active Application Filing
- 2006-11-20 WO PCT/EP2006/011134 patent/WO2007057228A1/en active Application Filing
- 2006-11-20 EP EP06818691A patent/EP1948610A2/en not_active Withdrawn
- 2006-11-20 CA CA002629834A patent/CA2629834A1/en not_active Abandoned
- 2006-11-20 AU AU2006314729A patent/AU2006314729A1/en not_active Abandoned
- 2006-11-20 WO PCT/EP2006/011133 patent/WO2007057227A1/en active Application Filing
-
2007
- 2007-08-08 IL IL185129A patent/IL185129A0/en unknown
- 2007-08-15 NO NO20074188A patent/NO20074188L/no not_active Application Discontinuation
-
2008
- 2008-12-12 US US12/334,124 patent/US20090093636A1/en not_active Abandoned
-
2009
- 2009-10-09 US US12/576,773 patent/US20100099879A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006314729A1 (en) | 2007-05-24 |
| CA2598093A1 (en) | 2007-05-24 |
| CA2629834A1 (en) | 2007-05-24 |
| US20070135480A1 (en) | 2007-06-14 |
| US7476748B2 (en) | 2009-01-13 |
| PT1954679E (pt) | 2011-05-05 |
| DE602006019979D1 (de) | 2011-03-17 |
| EP1960362A1 (en) | 2008-08-27 |
| US20070135642A1 (en) | 2007-06-14 |
| EP1954679A1 (en) | 2008-08-13 |
| WO2007057227A1 (en) | 2007-05-24 |
| AR057909A1 (es) | 2007-12-26 |
| AR057908A1 (es) | 2007-12-26 |
| WO2007057225A3 (en) | 2007-07-26 |
| CA2629840A1 (en) | 2007-05-24 |
| AU2006314726A1 (en) | 2007-05-24 |
| WO2007057225A2 (en) | 2007-05-24 |
| US7786138B2 (en) | 2010-08-31 |
| WO2007057228A1 (en) | 2007-05-24 |
| US7601741B2 (en) | 2009-10-13 |
| EP1954679B1 (en) | 2011-02-02 |
| US20090093636A1 (en) | 2009-04-09 |
| EP1948610A2 (en) | 2008-07-30 |
| IL185129A0 (en) | 2007-12-03 |
| US20070135643A1 (en) | 2007-06-14 |
| ATE497493T1 (de) | 2011-02-15 |
| AU2006314728A1 (en) | 2007-05-24 |
| NO20074188L (no) | 2008-08-13 |
| US20100099879A1 (en) | 2010-04-22 |
| JP2009515922A (ja) | 2009-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056815A1 (es) | PROCESO PARA PREPARAR MONTELUKAST, INTERMEDIARIOS DEL MISMO Y SUS SALES DE ADICIoN Y PROCEDIMIENTO DE PURIFICACIoN DE ÉSTOS Y DE MONTELUKAST | |
| Motherwell et al. | Free radical chain reactions in organic synthesis | |
| BRPI0822909B8 (pt) | sal de glicinato de metformina para o controle da glicose sanguínea | |
| TW472052B (en) | Process for preparing 1,4-benzodioxane derivatives | |
| ES2748692T3 (es) | Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la producción de moduladores FXR de esteroides | |
| AR057032A1 (es) | Tigeciclina y metodos de preparacion | |
| JP2014534261A5 (es) | ||
| RU2012116208A (ru) | Способ получения n-ацилбифенилаланина | |
| CY1113873T1 (el) | Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90 | |
| BRPI0508704A (pt) | métodos para a preparação de um composto e para a preparação de calcipotriol ou monoidrato de calcipotriol, composto, e, usos de um composto e de éster dietìlico do ácido (2-ciclopropil-2-oxoetil) fosfÈnico | |
| AR065775A1 (es) | Procedimiento para preparar 2,6-dicloro-4-(trifluorometil)-fenilhidracina usando mezclas de dicloro-fluoro-trifluorometilbencenos | |
| CO6290754A2 (es) | Método para producir bicarbonato de arginina | |
| AR099630A1 (es) | Preparación de un inhibidor de mek y formulación que lo comprende | |
| ES2711188T3 (es) | Procedimientos de preparación de compuestos de beta-aminosulfona | |
| BR112012012033A2 (pt) | processo para preparar ácido fórmico | |
| ES2278552T1 (es) | Preparacion de intermediarios de tadalafil. | |
| Yoshimitsu et al. | Radical α-C− H Hydroxyalkylation of Ethers and Acetal | |
| RU2015101998A (ru) | Получение 18F-флуцикловина | |
| AR107494A1 (es) | Proceso para la preparación de osimertinib (azd9291) o una sal del mismo, y azd9291 anilina o una sal de la misma | |
| ES2201166T3 (es) | Procedimiento de racemizacion para su utilizacion en la fabricacion de levobupivacaina y agentes anestesicos correspondientes a base de piperidincarboxanilida. | |
| BRPI0616169B8 (pt) | cloridrato de lercanidipina na forma polimorfa v, composição farmacêutica compreendendo dito composto e processos para preparação de cloridrato de lercanidipina | |
| AR052276A1 (es) | Proceso para preparar compuestos aromaticos biciclicos | |
| ES2866148T3 (es) | Método para producir 3,7-dimetil-7-octenol y método para producir compuesto de carboxilato de 3,7-dimetil-7-octenilo | |
| AR068807A1 (es) | Procedimiento de preparacion de benzodiazepinas. | |
| RU2009115852A (ru) | Способ получения абакавира |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |